Employees: 193
Size Beijing Luzhu Biotechnology (2480.HK) is a Hong Kong Health Care company (Biotechnology) with a market value of $396M, the 813th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$15.40 on 18 Nov 2026.
Performance Over six months the shares fell 32.9%, against -23.6% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 8th lowest of 21 in its peer set.
Valuation It trades at 26.2× forward earnings against a peer median of 50.1× (3rd cheapest of 5).
Capital Return on invested capital runs 25.7 points below its cost of capital (6.2% WACC).
Next results Next results expected around 24 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$0 | HK$0 | HK$0 | HK$0 | HK$0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -HK$41.1M | -HK$33.8M | -HK$27.1M | -HK$17.8M | -HK$11.5M |
| EBITDA | -HK$106M | -HK$128M | -HK$190M | -HK$269M | -HK$195M |
| Net income | -HK$150M | -HK$163M | -HK$182M | -HK$276M | -HK$843M |
| Free cash flow | -HK$176M | -HK$211M | -HK$193M | -HK$300M | -HK$387M |
| Capital expenditure | HK$56.3M | HK$66.5M | HK$107M | HK$96.3M | HK$299M |
| Total debt | n/a | HK$304M | HK$71.9M | HK$21.2M | HK$12.6M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 2480.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | 0.0% | -14.1% | 3rd highest of 21 |
| 6-month return | -32.9% | -23.6% | 8th lowest of 21 |
| Distance from 52-week high | -40.7% | -44.7% | 10th highest of 21 |
| Forward P/E | 26.2× | 50.1× | 3rd cheapest of 5 |
| ROIC minus cost of capital | -25.7 pp | -9.2 pp | 5th lowest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Beijing Luzhu Biotechnology 2480.HK | Hong Kong | $396M | -33% | n/a | n/a | 26.2× | n/a | n/a |
| Wuhan Hiteck Biological Pharma 300683.SZ | China | $395M | -41% | -30% | -27% | n/a | n/a | n/a |
| Shanghai Shen Lian Biomedical 688098.SS | China | $402M | -22% | -17% | -16% | n/a | n/a | n/a |
| Beijing Kawin Technology Share-Holding 688687.SS | China | $391M | -20% | +6% | -2% | 16.2× | 36.6% | +8.9% |
| Polynovo PNV.AX | Australia | $388M | -34% | +13% | 5% | 84.0× | 51.9% | +37.6% |
| Jacobio Pharmaceuticals 1167.HK | Hong Kong | $404M | -24% | +286% | 68% | 5.7× | -18.8% | -36.1% |
| Hubei Goto Biopharm 300966.SZ | China | $386M | -16% | +6% | -10% | n/a | n/a | n/a |
| Hanx Biopharmaceuticals (Wuhan) 3378.HK | Hong Kong | $409M | -24% | n/a | n/a | n/a | n/a | n/a |
| Edding Genor 6998.HK | Hong Kong | $410M | -35% | +1,418% | 26% | n/a | -15.3% | +197.3% |
| Alector ALEC | United States | $383M | +21% | +151% | 25% | n/a | n/a | n/a |
| Shanghai Obio Technology (Group) 688238.SS | China | $414M | -5% | +20% | -79% | n/a | n/a | n/a |
| PureTech Health PRTC.L | United Kingdom | $378M | -15% | -4% | -1,617% | n/a | n/a | n/a |
| Eupraxia Pharmaceuticals EPRX.TO | Canada | $416M | +1% | n/a | n/a | n/a | n/a | n/a |
| Shanghai Serum Bio-Technology 688163.SS | China | $416M | -34% | -1% | 26% | n/a | n/a | n/a |
| G2GBIO 456160.KS | South Korea | $416M | -53% | -45% | -2,884% | n/a | n/a | n/a |
| Candel Therapeutics CADL | United States | $417M | -31% | n/a | n/a | n/a | n/a | n/a |
| Rznomics 476830.KS | South Korea | $418M | -76% | -65% | -1,112% | n/a | n/a | n/a |
| Shanghai ZJ Bio-Tech 688317.SS | China | $422M | -22% | -10% | -72% | n/a | 4.0% | -62.3% |
| Guangdong Vtr Bio-Tech 300381.SZ | China | $370M | -31% | 0% | -4% | n/a | n/a | n/a |
| Medigen Vaccine Biologics 6547.TWO | Taiwan | $424M | -8% | +44% | -5% | 170.0× | n/a | n/a |
| Onconic Therapeutics 476060.KS | South Korea | $368M | -49% | +179% | 21% | n/a | 0.6% | +725.2% |